Australia Clinical Evidence Requirements: Schedule 3 Part 8 and TGA Guidelines

1. Key takeaways

Australian clinical evidence rests on two layers: the mandatory legal source is Schedule 3 Part 8 (clinical evaluation procedures) of the Therapeutic Goods (Medical Devices) Regulations 2002, together with regulation 3.11; the operational layer is the TGA’s “Clinical evidence guidelines for medical devices”, first published on 1 February 2017 and most recently updated on 11 September 2026, adding a chapter on computational modelling and simulation. Together the two layers set both a legal floor and a methodological ceiling for evidence, and every submission should be built to satisfy both at once. Facts verified as of 29 October 2026.

• Schedule 3 Part 8 is expressly “must be applied”, with the applicable device categories designated by regulation 3.11.
• Schedule 1 clause 14 requires each device to have clinical evidence appropriate to its use and classification; clause 15 states the IVD-only principle.
• The guideline history spans nine dated versions, from 1 February 2017 to 11 September 2026.
• The 11 September 2026 update adds a chapter on the use of computational modelling and simulation.
• Two companion guides — “Demonstrating evidence to comply with the Essential Principles” and “Real World Evidence” — were updated on the same date.

2. Legal basis

The clinical evidence obligations combine a mandatory Schedule 3 procedure with essential principles clauses and a TGA guideline that carries the operational detail. Because the guideline keeps evolving, the version date cited in a submission is itself part of the evidence quality story, and the two companion guides updated on the same date should also be consulted for evidence outside the device-specific chapters.

• Therapeutic Goods (Medical Devices) Regulations 2002 (F2002B00237, compilation F2026C00883): the clinical evaluation procedures are Schedule 3 Part 8 (regulation 8.1 and following), with the device categories that must apply them designated by regulation 3.11; the note to Schedule 3 Part 8 regulation 8.1 states expressly that it is mandatory (“must be applied”).
• Clinical evidence requirements at the essential principles level: Schedule 1 clause 14 — each device must be accompanied by clinical evidence appropriate to its use and its classification; clause 15 states the principle applicable to IVDs only.
• TGA guideline: “Clinical evidence guidelines for medical devices”, page states Published 1 February 2017, Last updated 11 September 2026; the latest version adds a chapter on the use of computational modelling and simulation.
• Version history (official page history): 1 November 2020 (CTA renamed); 1 March 2021 (comparable devices / substantial equivalence); 1 November 2021; 1 June 2022 (new chapters on personalised medical devices and SaMD); 23 November 2023 (new chapters on ophthalmic devices and drug-device combinations); 31 October 2024 (title changed to “Meeting clinical evidence requirements for medical devices”); 11 September 2026 (computational modelling and simulation added).
• Same-day updates (all 11 September 2026): “Demonstrating evidence to comply with the Essential Principles” and “Real World Evidence”.
• Practical estimate: the specific written conditions for clinical evidence exemptions (literature-based / equivalence routes) have not been located as exact clause numbers on the official pages.

3. Expert insights

Insight 1: Part 8 is part of the CAPs, not “additional material”. The clinical evaluation procedures are written into Schedule 3 and apply mandatorily, which means they stand alongside quality system audits and type examination in the legal structure. Preparing them with the European mindset of “a chapter inside the technical file” invites a finding of an incomplete evidence chain at audit, because the Australian instrument does not treat clinical evaluation as a subordinate annex. A submission that cites Part 8 explicitly, and maps its evidence to the procedure step by step, is far harder to fault on completeness grounds. The reverse also holds: strong clinical data does not excuse skipping the procedural requirements of Part 8.

Insight 2: the 11 September 2026 version writes computational modelling and simulation into the guideline. This is a substantive benefit for innovative devices without clinical trial data, but it also means the TGA will expect validation, verification and uncertainty analysis of the modelling and simulation. When citing this route, the argument on evidence strength must be front-loaded rather than left for reviewer questions. Where modelling supports the evidence, the justification for why clinical data is not required should be drafted alongside the model documentation, not after it.

Insight 3: the guideline is chaptered by device type, and the version differences are large. Personalised devices and SaMD were added in 2022; ophthalmic and drug-device combinations in 2023. Companies in these categories that still operate on a 2017-era understanding of the guideline will miss the device-specific chapter requirements entirely, because those chapters did not exist in the version their templates were written against. A short internal mapping of the current guideline against each product category is therefore worth doing before any new submission is drafted.

4. Practical recommendations

• Cite in two layers, “legal source plus guideline”: write Schedule 3 Part 8 and regulation 3.11 as the legal basis, and cite the guideline with its version date of 11 September 2026 for evidence organisation, so a reviewer can trace every claim back to a dated source.
• Locate the guideline chapter for the device type (SaMD, personalised, ophthalmic, drug-device combination) instead of relying only on the generic chapter, and note in the CER which chapter governed each evidence element.
• For projects using computational modelling and simulation, prepare the model validation, verification and uncertainty analysis documents in advance.
• For Class III and IVD projects, plan the clinical evidence together with the additional information requirements described in the companion article, to avoid duplicated work.

5. Verification checklist

• □ Whether the product falls within the Part 8 mandatory scope designated by regulation 3.11 has been confirmed
• □ The clinical evidence file cites Schedule 3 Part 8 as the legal source
• □ The guideline citation states the 11 September 2026 version
• □ The device-specific guideline chapter has been located
• □ Validation and verification documents are ready for the computational modelling and simulation route

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team manages TGA ARTG inclusion across all classes, prepares conformity assessment dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanlang.com